共查询到20条相似文献,搜索用时 15 毫秒
1.
C. V. HUTCHINSON J. BURTHEM M. BISLAND P. CAREY G. CROTTY V. DEVALIA B. JANDA W. GORDON C. N. HARRISON J. MURRAY A. SHLEBAK A. THOMAS B. WILKINS M. F. McMULLIN 《International journal of laboratory hematology》2010,32(2):174-183
A morphology session is held each year at the Annual Scientific Meeting of the British Society of Haematology. Prior to the meeting this year, eight morphology cases were made available to BSH members as glass slides and also digitally as ‘virtual slides’. A panel of invited commentators who had no prior knowledge of the diagnosis discussed the eight cases. An initial limited history and blood count are given with representative images from the case material; this is followed by the discussants’ comments and suggested diagnosis. The actual clinical diagnosis is then given with other relevant information. 相似文献
2.
3.
4.
5.
Bain BJ Goldman JM Lucie NP Brito-Babapulle F Bhavnani M Kubie A Jan-Mohamed R Pocock M Layton M 《Clinical and laboratory haematology》2004,26(2):87-93
Seven patients who had a diagnostic problem were presented at the British Society for Haematology, Annual Scientific Meeting in 2003. The likely diagnosis was discussed on the basis of a synopsis of the history and blood film and trephine biopsy features and forms the basis of this report. Diagnostic problems dealt with included lymphoproliferative and myeloproliferative disorders and haemolytic anaemia. 相似文献
6.
Bain BJ 《Clinical and laboratory haematology》2006,28(6):363-369
Eight cases discussed by experts at the 2006 Annual Scientific Meeting of the British Society for Haematology are presented as at the meeting, with a discussion of the morphological features and differential diagnosis being followed by further information and a final diagnosis. 相似文献
7.
8.
9.
10.
Bhavnani M Braithwaite J Burthem J Crotty G Gibson B Hutchinson C Jackson GH Layton M Lucas G Macartney C Matthey F Pardoe L Radia D Webb S 《International journal of laboratory hematology》2008,30(2):95-104
Eight cases discussed by experts at the 2007 Annual Scientific Meeting of the British Society of Haematology are presented as at the meeting, with a discussion of the morphological features, digital information and differential diagnosis being followed by further information and a final diagnosis. Additionally, digital slides of two of the cases were available to be viewed by the internet with the opportunity for delegates to suggest diagnoses. 相似文献
11.
12.
13.
14.
15.
16.
17.
Bain BJ Murray JA Patterson KG Chakravorty S Ancliff P Wong CC Hann I Wong C Philpott N Bolam S Thomas W 《Clinical and laboratory haematology》2005,27(6):363-369
Each year at the Annual Scientific Meeting of the British Society for Haematology, there is a slide session in which microscopic slides of six patients with haematological disorders are discussed by two experts. Further data and the final diagnosis are then provided. The slide session is presented here, as it occurred at the meeting. 相似文献
18.
19.
20.
Saif MW 《JOP : Journal of the pancreas》2006,7(4):337-348
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. Combination chemotherapy trials incorporating gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, or irinotecan generally show improved outcomes in objective response rates but with little or no improvement in survival in phase III trials. In this article, the author describes the key studies presented at the Annual Meeting of ASCO, held in Atlanta, GA from June 2nd to 6th. The studies discussed here include the following: RTOG 9704 (#4007), FFCD-SFRO study (#4008), meta-analysis of gemcitabine plus cisplatin and gemcitabine plus oxaliplatin vs. gemcitabine alone (GERCOR #4003), and ECOG 6201 (Late Breaking Abstract #4004). Based on the results presented at the annual meeting, it comes to us that patients with locally advanced vs. metastatic pancreatic cancer should be studied separately, better understanding of the biology of pancreatic cancer is mandatory and evaluation of novel agents is crucial. We as oncologist have to change our attitudes towards clinical trials and need to think beyond a trial design such as gemcitabine vs. drug of our choice. Environment within which research is being conducted also has to be changed and last but not the least, access to trials for patients with pancreatic cancer is the key step in the fight against pancreatic cancer. 相似文献